Cell contact dependence of inflammatory events

Contemporary Targeted Therapies in Rheumatology

Volumn , Issue , 2007, Pages 85-103

  Burger, Danielle ^a   Dayer, Jean Michel ^a   Molnarfi, Nicolas ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44749091522     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (155)

1. Burger D, Dayer JM. Inhibitory cytokines and cytokine inhibitors. Neurology 1995; 45: S39-S43.
2. Burger D, Dayer JM. The balance between pro- and antiinflammatory cytokines. In: Smolen JS, Lipsky PE, eds.Targeted Therapies in Rheumatology. London: Martin Dunitz, 2003: 329-43.
3. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005; 52(7): 1960-7.
4. Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005; 7(16): 1-20.
5. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004; 31(6): 1103-11.
6. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41(10): 1126-32.
7. Lorenz HM, Kalden JR. Perspectives for TNF-alpha-targeting therapies. Arthritis Res 2002; 4(Suppl 3):S17-S24.
8. Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res 2002; 4(Suppl 2): S34-S40.
9. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol2002; 29(1): 118-22.
10. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002; 16(2): 127-9.
11. Sfikakis PP. Behçet's disease: A new target for antitumour necrosis factor treatment. Ann Rheum Dis 2002; 61(Suppl 2): 1151-1153.
12. Lee RZ, Veale DJ. Management of spondyloarthropathy: new pharmacological treatment options. Drugs2002; 62(16): 2349-59.
13. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16(3): 361-78.
14. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004; 76(3): 509-13.
15. Tracey KJ. The inflammatory reflex. Nature 2002; 420(6917): 853-9.
16. Daems WT, de Bakker JM. Do resident macrophages proliferate? Immunobiology 1982; 161(3-4): 204-11.
17. Metcalf D, Elliott MJ, Nicola NA. The excess numbers of peritoneal macrophages in granulocyte-macrophage colony-stimulating factor transgenic mice are generated by local proliferation. J Exp Med 1992; 175(4): 877-84.
18. Chen BD, Mueller M, Chou TH. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988; 141(1): 139-44.
19. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: Analysis using a transgenic bone marrow transplantation model. Blood 1997; 90(3): 986-93.
20. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol2001; 70(2): 163-70.
21. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: A review of function and identification. J Leukoc Biol 2004; 75(3): 388-97.
22. Meldrum DR, Cleveland JC Jr, Moore EE et al. Adaptive and maladaptive mechanisms of cellular priming. Ann Surg 1997; 226(5): 587-98.
23. Stout RD, Suttles J. T-cell signaling of macrophage activation: cell contact-dependent and cytokine signals. New York: Springer, 1995.
24. Gordon S, Fraser I, Nath D, Hughes D, Clarke S. Macrophages in tissues and in vitro. Curr Opin Immunol1992; 4(1): 25-32.
25. Ziegler-Heitbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today1993; 14: 121-5.
26. Passlick B, Flieger D, Ziegler-Heitbrock HWL. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-34.
27. Ziegler-Heitbrock HW, Fingerle G, Strobel M et al. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. Eur J Immunol1993; 23(9): 2053-8.
28. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HW. Differential cytokine expression in human blood monocyte subpopulations: A polymerase chain reaction analysis. Blood 1996; 87(1): 373-7.
29. Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: The CD14+ CD16+ subpopulation. Immunol Today 1996; 17(9): 424-8.
30. Siedlar M, Frankenberger M, Ziegler-Heitbrock LH, Belge KU. The M-DC8-positive leukocytes are a subpopulation of the CD14+ CD16+ monocytes. Immunobiology 2000; 202(1): 11-17.
31. de Baey A, Mende I, Riethmueller G, Baeuerle PA. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. Eur J Immunol2001; 31(6): 1646-55.
32. Fingerle G, Pforte A, Passlick B et al. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood 1993; 82(10): 3170-6.
33. Kawanaka N, Yamamura M, Aita T et al. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002; 46(10): 2578-86.
34. Cairns AP, Crockard AD, Bell AL. The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus. Rheumatol Int 2002; 21(5): 189-92.
35. Then BF, Dayyani F, Ziegler-Heitbrock L. Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol 2004; 146(1-2): 176-88.
36. Kouwenhoven M, Teleshova N, Ozenci V, Press R, Link H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol 2001; 112(1-2): 197-205.
37. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3(1): 23-35.
38. Stout RD, Suttles J. T cell signaling of macrophage function in inflammatory disease. Front Biosci 1997; 2: 197-206.
39. Tak PP, Smeets TJM, Daha MR et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 217-25.
40. Smeets TJ, Kraan MC, Galjaard S et al. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001; 60(6): 561-5.
41. Davis LS, Geppert TD, Meek K, Oppenheimer-Marks N, Lipsky PE. Immune and inflammatory responses. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CS, eds.Textbook of Rheumatology. Philadelphia: WB Saunders, 1997: 95-127.
42. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001; 15(5): 677-91.
43. Elliott CL, El Touny SY, Filipi ML, Healey KM, Leuschen MP. Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients. J Clin Immunol2001; 21(3): 200-9.
44. Laman JD, Thompson EJ, Kappos L. Balancing the Th1/Th2 concept in multiple sclerosis. Immunol Today1998; 19(11): 489-90.
45. Wong WM, Vakis SA, Ayre KR et al. Rheumatoid arthritis T cells produce Th1 cytokines in response to stimulation with a novel trispecific antibody directed against CD2, CD3, and CD28. Scand J Rheumatol 2000; 29(5): 282-7.
46. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005; 7(Suppl 2): S4-S14.
47. Harris ED. Rheumatoid Arthritis. Philadelphia: WB Saunders, 1997.
48. Vey E, Zhang JH, Dayer J-M. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol 1992; 149: 2040-6.
49. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T-cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69. Eur Cytokine Netw 1993; 4: 15-23.
50. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994; 269: 22027-33.
51. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3: 189-95.
52. Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production. Role of T cell membrane TNF-alpha. J Immunol 1997; 158: 3673-81.
53. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997; 27: 624-32.
54. Avice MN, Demeure CE, Delespesse G et al. IL-15 promotes IL-12 production by human monocytes via T cell-dependent contact and may contribute to IL-12-mediated IFN-gamma secretion by CD4+ T cells in the absence of TCR ligation. J Immunol 1998; 161(7): 3408-15.
55. Avice MN, Sarfati M, Triebel F, Delespesse G, Demeure CE. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-alpha production by monocytes and dendritic cells. J Immunol 1999; 162(5): 2748-53.
56. Chabot S, Charlet D, Wilson TL, Yong VW. Cytokine production consequent to T cell-microglia interaction: The PMA/IFN gamma-treated U937 cells display similarities to human microglia. J Neurosci Methods 2001; 105(2): 111-20.
57. Burger D, Roux-Lombard P, Chizzolini C, Dayer JM. Cell-cell contact in chronic inflammation: The importance to cytokine regulation in tissue destruction and repair. In: van den Berg WB, Miossec P, eds. Cytokines and Joint Injury. Basel: Birkhäuser Verlag, 2004: 165-88.
58. Burger D. Cell contact-mediated signaling of monocytes by stimulated T cells: A major pathway for cytokine induction. Eur Cytokine Netw 2000; 11(3): 346-53.
59. Molnarfi N, Gruaz L, Dayer JM, Burger D. Opposite effects of IFNbeta on cytokine homeostasis in LPS-and T cell contact-activated human monocytes. J Neuroimmunol 2004; 146(1-2): 76-83.
60. Weaver CT, Unanue ER. T cell induction of membrane IL-1 on macrophages. J Immunol 1986; 137: 3868-73.
61. Landis CB, Friedman ML, Fisher RI, Ellis TM. Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals. J Immunol 1991; 146: 128-35.
62. Cutolo M, Capellino S, Montagna P et al. Antiinflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. Ann Rheum Dis 2006; 65: 728-35.
63. Dasgupta S, Jana M, Liu X, Pahan K. Role of very-late antigen-4 (VLA-4) in myelin basic protein-primed T cell contact-induced expression of proinflammatory cytokines in microglial cells. J Biol Chem 2003; 278(25): 22424-31.
64. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b. J Clin Invest 1997; 100: 604-12.
65. Brennan FM, Hayes AL, Ciesielski CJ et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 2002; 46(1): 31-41.
66. Li JM, Isler P, Dayer JM, Burger D. Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones. Immunology 1995; 84: 571-6.
67. Vey E, Burger D, Dayer JM. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol 1996; 26: 2404-9.
68. Vey E, Dayer JM, Burger D. Direct contact with stimulated T cells induces the expression of IL-1 beta and IL-1 receptor antagonist in human monocytes. Involvement of serine/threonine phosphatases in differential regulation. Cytokine 1997; 9: 480-7.
69. Chizzolini C, Chicheportiche R, Burger D, Dayer JM. Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol 1997; 27(1): 171-7.
70. Chabot S, Williams G, Hamilton M, Sutherland G, Yong VW. Mechanisms of IL-10 production in human microglia-T cell interaction. J Immunol 1999; 162(11): 6819-28.
71. Dunlap NE, Tilden AB. T helper/inducer (CD4+) cells prestimulated with PPD induce monocytes to produce interleukin-1β. J Leukoc Biol 1991; 49: 542-7.
72. Ribbens C, Dayer JM, Chizzolini C. CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2- or interleukin-15-driven, contact-dependent, interleukin-1beta production by monocytes. Immunology2000; 99(2): 279-86.
73. Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 2004; 50(2): 432-43.
74. Foey AD, Feldmann M, Brennan FM. Route of monocyte differentiation determines their cytokine production profile: CD40 ligation induces interleukin 10 expression. Cytokine 2000; 12(10): 1496-505.
75. Foey AD, Feldmann M, Brennan FM. CD40 ligation induces macrophage IL-10 and TNF-alpha production: Differential use of the PI3K and p42/44 MAPK-pathways. Cytokine 2001; 16(4): 131-42.
76. Burger D, Molnarfi N, Gruaz L, Dayer JM. Differential induction of IL-1beta and TNF by CD40 ligand or cellular contact with stimulated T cells depends on the maturation stage of human monocytes. J Immunol 2004; 173(2): 1292-7.
77. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996; 156(1): 8-11.
78. Suttles J, Milhorn DM, Miller RW et al. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (IL)- 4 and IL-10 anti-inflammatory action. J Biol Chem1999; 274(9): 5835-42.
79. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol 2005; 78(1): 135-43.
80. Déage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metallo-proteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw 1998; 9(4): 663-8.
81. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001; 14(5): 272-82.
82. Chabot S, Yong FP, Le DM et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: A mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002; 8(4): 299-306.
83. Hyka N, Dayer JM, Modoux C et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97(8): 2381-9.
84. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: The missing link between infection and chronic inflammation? Autoimmun Rev 2002; 1: 111-17.
85. Soma MR, Donetti E, Parolini C et al. Recombinant apolipoprotein A-IMilano dimer inhibits carotid inti-mal thickening induced by perivascular manipulation in rabbits. Circ Res 1995; 76(3): 405-11.
86. Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996; 71(3): 155-64.
87. Rossol M, Kaltenhauser S, Scholz R et al. The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis. Arthritis Res Ther 2005; 7(6): R1189-R1199.
88. Bresnihan B, Gogarty M, Fitzgerald O, Dayer J-M, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: A control mechanism of cytokine production? Arthritis Res Ther 2004; 6: R563-R566.
89. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002; 9(1): 2-10.
90. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406(6797): 782-7.
91. Beutler B. Inferences, questions and possibilities in Tolllike receptor signalling. Nature 2004; 430(6996): 257-63.
92. Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: Translational signal provided by lipopolysaccharide or IL-1 itself. Blood 1990; 76(8): 1631-8.
93. Hayes AL, Smith C, Foxwell BM, Brennan FM. CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor- kappaB-independent. J Biol Chem1999; 274(47): 33455-61.
94. Foey AD, Green P, Foxwell B, Feldmann M, Brennan F. Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis. Arthritis Res 2002; 4: 64-70.
95. Foxwell BM, Browne K, Bondeson J et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 1998; 95(14): 8211-15.
96. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D. The production of IL-1 receptor antagonist in IFN-(beta)-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 2005; 174(5): 2974-80.
97. Molnarfi N, Gruaz L, Dayer JM, et al. Opposite regual-tion of IL-1beta and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccarides or contact with T cells J Immunol 2007; 178(1):446-454.
98. Learn CA, Boger MS, Li L, McCall CE. The phosphatidylinositol 3-kinase pathway selectively controls sIL-1RA not interleukin-1beta production in the septic leukocytes. J Biol Chem 2001; 276(23): 20234-9.
99. Martin M, Schifferle RE, Cuesta N et al. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 2003; 171(2): 717-25.
100. Burger D, Dayer JM. Cell-cell interactions in chronic inflammation: modulation of surrounding cells by direct contact with stimulated T lymphocytes. In: Schneider CH, ed. Peptides in Immunology. Chichester: John Wiley and Sons, 1996: 159-64.
101. Williamson RA, Yea CM, Robson PA et al.Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc 1996; 28(6): 3088-91.
102. Tugwell P, Wells G, Strand V et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43(3): 506-14.
103. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43(3): 495-505.
104. Arnason BG. Treatment of multiple sclerosis with interferon beta. Biomed Pharmacother 1999; 53(8): 344-50.
105. Tak PP. IFN-beta in rheumatoid arthritis. Front Biosci2004; 9: 3242-7.
106. Burger D, Begue-Pastor N, Benavent S et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42(1): 89-96.
107. Palmer G, Burger D, Mezin F et al. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther2004; 6(3): R181-R189.
108. Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1 beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997; 8: 345-9.
109. Suresh E, Morris IM, Mattingly PC. Use of minocycline in rheumatoid arthritis: A district general hospital experience. Ann Rheum Dis 2004; 63(10): 1354-5.
110. O'Dell JR, Blakely KW, Mallek JA et al. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001; 44(10): 2235-41.
111. O'Dell JR, Paulsen G, Haire CE et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebocontrolled trial. Arthritis Rheum 1999; 42(8): 1691-5.
112. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med 1994; 96(5): 457-62.
113. Fox HS. Sex steroids and the immune system. Ciba Found Symp 1995; 191: 203-11.
114. Cutolo M. Do sex hormones modulate the synovial macrophages in rheumatoid arthritis? Ann Rheum Dis1997; 56(5): 281-84.
115. Cutolo M, Sulli A, Capellino S et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13(9): 635-8.
116. Cutolo M, Capellino S, Montagna P et al. Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line. Arthritis Res Ther2005; 7(5): R1124-R1132.
117. Dasgupta S, Jana M, Liu X, Pahan K. Myelin basic protein-primed T cells of female but not male mice induce nitric-oxide synthase and proinflammatory cytokines in microglia: implications for gender bias in multiple sclerosis. J Biol Chem 2005; 280: 32609-17.
118. Dinther-Janssen AC, Pals ST, Scheper R, Breedveld F, Meijer CJ. Dendritic cells and high endothelial venules in the rheumatoid synovial membrane. J Rheumatol1990; 17(1): 11-17.
119. Kang YM, Zhang X, Wagner UG et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002; 195(10): 1325-36.
120. De Vita S, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46(8): 2029-33.
121. Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000; 2(2): 126-31.
122. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: Dual immunolocalisation studies. Ann Rheum Dis 1995; 54(11): 896-903.
123. Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis 1995; 54(7): 549-55.
124. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11(3): 156-64.
125. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: Two sides of the coin. Physiology 2005; 20: 22-7.
126. Berckmans RJ, Neiuwland R, Boing AN et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85(4): 639-46.
127. Joop K, Berckmans RJ, Nieuwland R et al.Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85(5): 810-20.
128. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96(10): 3534-41.
129. Nieuwland R, Berckmans RJ, McGregor S et al.Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95(3): 930-5.
130. Osmanovic N, Romijn FP, Joop K, Sturk A, Nieuwland R. Soluble selectins in sepsis: microparticle-associated, but only to a minor degree. Thromb Haemost 2000; 84(4): 731-2.
131. Fujimi S, Ogura H, Tanaka H et al. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002; 52(3): 443-8.
132. Ogura H, Kawasaki T, Tanaka H et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50(5): 801-9.
133. Geisbert TW, Young HA, Jahrling PB et al.Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188(11): 1618-29.
134. Combes V, Simon AC, Grau GE et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104(1): 93-102.
135. Brogan PA, Shah V, Brachet C et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004; 50(3): 927-36.
136. Minagar A, Jy W, Jimenez JJ et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56(10): 1319-24.
137. Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 46(6): 1498-503.
138. Berckmans RJ, Nieuwland R, Tak PP et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002; 46(11): 2857-66.
139. Distler JH, Jungel A, Huber LC et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A 2005; 102(8): 2892-7.
140. Berckmans RJ, Nieuwland R, Kraan MC et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 2005; 7(3): R536-R544.
141. Distler JH, Pisetsky DS, Huber LC et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005; 52(11): 3337M8.
142. Miltenburg AMM, Lacraz S, Welgus HG, Dayer JM. Immobilized anti-CD3 antibody activates T cell clones to induce the production of interstitial collagenase, but not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal fibroblasts. J Immunol1995; 154: 2655-67.
143. Lou J, Dayer JM, Grau GE, Burger D. Direct cell/cell contact with stimulated T lymphocytes induces the expression of cell adhesion molecules and cytokines by human brain microvascular endothelial cells. Eur J Immunol 1996; 26: 3107-13.
144. Rezzonico R, Burger D, Dayer JM. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines. J Biol Chem 1998; 273(30): 18720-8.
145. Burger D, Rezzonico R, Li JM et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum 1998; 41(10): 1748-59.
146. Dinther-Janssen AC, Horst E, Koopman G et al. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 1991; 147(12): 4207-10.
147. Matsuyama T, Kitani A. The role of VCAM-1 molecule in the pathogenesis of rheumatoid synovitis. Hum Cell1996; 9(3): 187-92.
148. Postigo AA, Garcia-Vicuna R, Diaz-Gonzalez F et al.Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1). J Clin Invest 1992; 89(5): 1445-52.
149. Washington R, Burton J, Todd RF et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol1994; 35: 89-97.
150. Burger D, Lou J, Dayer JM, Grau GE. Both soluble and membrane-associated TNF activate brain microvascular endothelium: relevance to multiple sclerosis. Mol Psychiatry 1997; 2(2): 113-16.
151. Monaco C, Andreakos E, Young S, Feldmann M, Paleolog E. T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol 2002; 71(4): 659-68.
152. Feldmann M, Maini RN. Anti TNF-alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
153. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002; 4(Suppl 2): S22-S28.
154. Cettour-Rose P, Nguyen TX, Serrander L et al. T cell contact-mediated activation of respiratory burst in human polymorphonuclear leukocytes is inhibited by high-density lipoproteins and involves CD18. J Leukoc Biol 2005; 77(1): 52-8.
155. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood 2004; 104(8): 2543-8.